COCRYSTAL PHARMA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
COCRYSTAL PHARMA, INC. (COCP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.12 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-31
- COCRYSTAL PHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $1.12M, a 26.27% increase from fiscal 2023.
- COCRYSTAL PHARMA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $890.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $1.12M 10-K · filed 2025-03-31 |
| 2023-12-31 | $890.00K 10-K · filed 2024-03-28 |
| 2022-12-31 | $805.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |